Enovis Corporation
0I1B.L
London Stock Exchange25.50
USD
+0.62
- -
Enovis Corporation
0I1B.L
(London Stock Exchange)
Recent
price
25.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Enovis Corporation operates as a global medical technology innovator. The company designs, manufactures, and distributes advanced medical devices intended for use by orthopedic specialists, surgeons, primary care doctors, pain management experts, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. These solutions address patients dealing with musculoskeletal conditions stemming from degenerative diseases, physical deformities, traumatic injuries, and sports-related incidents. Their comprehensive portfolio is divided into two key segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers products such as rigid and soft orthopedic bracing, systems for hot and cold therapy, bone growth stimulators, vascular therapy solutions, compression garments, therapeutic footwear and inserts, electrical stimulation devices for managing discomfort, and various physical therapy tools. The Reconstructive segment provides a suite of surgical implant products for the hip, knee, shoulder, elbow, foot, ankle, and finger, alongside advanced surgical productivity instruments, including augmented reality systems for guidance. Enovis distributes its offerings both directly and through a network of independent channels, reaching healthcare providers and specialized retail outlets under brands like DJO. The company, which originated as Colfax Corporation, completed its transformation and rebranded to Enovis in 2022, and is headquartered in Wilmington, Delaware. Recent strategic moves include the significant 2024 acquisition of LimaCorporate, enhancing its reconstructive joint offerings, and the 2025 sale of its Dr. Comfort diabetic shoe business.